Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Date Founded



222 Berkeley Street, 12th Floor, Boston, MA, 02116, USA

Type of Company


Employees (Worldwide)




Company Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Rhythm Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman, President & Chief Executive Officer

Chief Financial Officer

Senior Vice President & General Counsel

Chief Medical Officer

Chief Human Resources Officer

Executive Vice President, Head of International

Executive Vice President, Head of North America

Vice President & Head of Research

Senior Vice President, Technical Operations

Senior Vice President-Strategy & Corporate Development

Board of Directors

Chairman, President & Chief Executive Officer at Rhythm Pharmaceuticals, Inc.

Executive Vice President & Chief Commercial & Operations Officer at Vertex Pharmaceuticals, Inc.

Chief Medical Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc.

Co-Founder, President & Chief Executive Officer at Trevi Therapeutics, Inc.

Former Executive Vice President-Human Resources & Corporate Affairs at AstraZeneca Plc

Executive Officer, Director at Adolor Corp.

General Partner at New Enterprise Associates, Inc.

President at Turmeric Acquisition Corp.

Senior Advisor at JSB-Partners LP

Paths to Rhythm Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
Rhythm Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment and philanthropy—all toward the end goal of cures for disease, improved quality of life and reduced cost of care. As of late 2019, the firm manages nearly $10 billion in assets. Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company. Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries. Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.

Details Hidden

MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health.MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research

Recent Transactions
Details Hidden

Rhythm Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Rhythm Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Rhythm Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock


Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock


Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onRhythm Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants

Chief Executive Officer at Excellentia Global Partners

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Total Debt
Net Profit
Total Equity
TEVNet Income
Debt TEV
Non-Profit Donations & Grants
$5,000 - $10K
Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

Orbimed Advisors Private Equity seeks investment opportunities in private and public healthcare companies located in globally primarily North America, Asia, Europe and Israel. The firm targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage capital for large publicly traded companies.

Details Hidden

Deerfield Management Co. LP invests in companies located in the US. The firm target companies operating in broad range of industries. They provides financing for buyout transactions to private and public.

Ipsen SA Pharmaceuticals | Boulogne-billancourt, France

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Camurus AB Hospitals & Patient Services | Lund, Sweden

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Recipharm AB Industrial Machinery & Manufacturing | Jordbro, Sweden

Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rhythm Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rhythm Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Rhythm Pharmaceuticals, Inc..